pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$MIRMMirum Pharmaceuticals, Inc.

$MIRM96.13+0.65%
Foster City, CA, USupdated 30m ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
6
marketed
3
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(6)

pipeline depth6 products
Phase 2: 2Phase 3: 1Marketed: 3
2Phase 21Phase 33Marketed
Marketed
Chenodiol Mirum
Gall Stone
Marketed
cholic acid
Inherited Metabolic Disorders
Marketed
maralixibat chloride
Biliary Atresia
Ileal sodium/bile acid cotransporter
Phase 3
brelovitug
Hepatitis D
Phase 2
MRM-3379
Fragile X Syndrome
Phase 2
volixibat potassium
Pruritus

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 4, 2026
earnings
$MIRM96.13+0.65%
17d ago
Mirum Pharmaceuticals, Inc. earnings
Mirum Pharmaceuticals, Inc.
→
view all catalysts →

Active trials

  • —Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitugavailable
  • phase3Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtiderecruitingn=120
  • —Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)recruitingn=70
  • phase2Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)recruitingn=60
  • phase2MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)not yet recruitingn=15
  • phase2A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)active not recruitingn=182
  • —The REPLACE Registry for Cholbam® (Cholic Acid)active not recruitingn=55
  • phase2A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitisrecruitingn=260
🐶 Hiring Signal
No open roles indexed yet — view Mirum Pharmaceuticals, Inc. jobs →

News

  • BioSpace 2027 Best Places to Work shines light on most admired employers
    The list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.
    biospace · 10d ago
  • Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
    Vir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.
    biospace · 11d ago
identifiers
ticker
$MIRM
SEC CIK
0001759425
country
US
source
sec_tickers
top tags
Dermatology1Infectious Disease1
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 3m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?